+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cancer Cachexia (CC) - Epidemiology Forecast-2030

  • ID: 5023873
  • Report
  • April 2020
  • Region: Global
  • 86 pages
  • DelveInsight
1 of 2
This report delivers an in-depth understanding of the Cancer Cachexia, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Cancer Cachexia (CC) Disease Understanding

In 2011, an International consensus defined “Cancer cachexia as a multifactorial syndrome defined by the ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment” (Fearon, Lancet Oncol 2011). The pathophysiology of the syndrome is characterized by a negative protein and energy balance that is driven by a variable combination of reduced food intake, or anorexia, and abnormal metabolism.

Cancer cachexia is a continuum with three stages of clinical relevance: precachexia, cachexia, and refractory cachexia. Not all patients traverse the entire spectrum. In precachexia, early clinical and metabolic signs (e.g., anorexia and impaired glucose tolerance) can precede substantial involuntary weight loss (i.e., ≤5%). The risk of progression varies and depends on factors such as cancer type and stage, the presence of systemic inflammation, low food intake, and lack of response to anticancer therapy.

Cancer Cachexia (CC) Epidemiology

The Cancer Cachexia epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Cancer Cachexia epidemiology segmented as the Total prevalence of Cancer Cachexia, Gender-Specific cases of Cancer Cachexia, and Cancer Cachexia cases based on tumor. The report includes the prevalent scenario of Cancer Cachexia symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Cancer Cachexia (CC) Epidemiology

The total prevalent population of Cancer Cachexia in 7MM countries was estimated to be 1,218,895 in 2017.
  • As per the estimates, the United States has the highest prevalent population of Cancer Cachexia
  • Among the EU5 countries, Germany had the highest prevalent population of Cancer Cachexia, followed by France. On the other hand, Spain had the lowest prevalent population with 65,505 cases in 2017.
Scope of the Report
  • Cancer Cachexia (CC) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • Cancer Cachexia (CC) Epidemiology Report and Model provide an overview of the risk factors and global trends of Cancer Cachexia (CC) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Cancer Cachexia (CC) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Cancer Cachexia
  • The report provides the segmentation of the Cancer Cachexia (CC) epidemiology by Prevalent Cases of Cancer Cachexia (CC) in 7MM
  • The report provides the segmentation of the Cancer Cachexia (CC) epidemiology by gender-specific Prevalent Cases of Cancer Cachexia (CC) in 7MM
  • The report provides the segmentation of the Cancer Cachexia (CC) epidemiology based on major tumors in 7MM
Report Highlights
  • 11-Year Forecast of Cancer Cachexia (CC) epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Cancer Cachexia (CC)
  • Prevalent Cases according to segmentation: Gender-specific Prevalence of Cancer Cachexia (CC)
  • Cancer Cachexia cases based on Tumor Type
KOL - Views

The publisher interviews, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Cancer Cachexia (CC)?
  • What are the key findings pertaining to the Cancer Cachexia (CC) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Cancer Cachexia (CC) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Cancer Cachexia?
  • What are the currently available treatments of Cancer Cachexia?
Reasons to Buy

The Cancer Cachexia (CC) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Cancer Cachexia (CC) market
  • Quantify patient populations in the global Cancer Cachexia (CC) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Cancer Cachexia (CC) therapeutics in each of the markets covered
  • Understand the magnitude of Cancer Cachexia (CC) population by its Prevalence cases
  • Understand the magnitude of Cancer Cachexia (CC) population by its Gender-specific cases
  • Understand the magnitude of Cancer Cachexia (CC) population by its tumor type.
  • The Cancer Cachexia (CC) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Cancer Cachexia (CC) Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

According to Fox et al, the proportion of patients with cachexia varied considerably depending upon the definition employed, indicating that a standard well-accepted definition of cachexia is needed to improve clinical research, diagnosis and treatment of cachexia, and work is underway.

Arthur et al. recently estimated the annual prevalence of cachexia using data from the Nationwide Inpatient Sample, attributed hospital admissions to community hospitals in the US at over 160,000 cases. The median duration of stay was 6 days, compared with 3 days for non-cachexia admissions. In the industrialized world like Europe, the overall prevalence of cachexia is growing with the growth of chronic illness prevalence.
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Cancer Cachexia (CC): Patient Overview at a Glance
2.1. Total Patient Share (%) Distribution of Cancer Cachexia in 2017
2.2. Total Patient Share (%) Distribution of Cancer Cachexia in 2030

3. Executive summary

4. Organizations

5. Epidemiology Methodology

6. Cancer Cachexia (CC): Disease Overview
6.1.1. Introduction
6.1.2. Stages of cachexia
6.1.3. Signs and Symptoms
6.1.4. Causes and Risk Factors
6.1.5. Clinical Manifestations
6.1.6. Pathophysiology
6.1.7. Diagnosis
6.1.8. Biomarkers of cachexia

7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Total prevalent cases of Cancer Cachexia in 7MM
7.3. Country Wise-Epidemiology of Cancer Cachexia
7.4. United States
7.5. Assumptions and Rationale
7.6. Total prevalent cases of Cancer Cachexia in the United States
7.7. Cancer Cachexia cases based on tumor type in the United States
7.8. Gender-Specific cases of Cancer Cachexia in the United States
7.9. EU5 Countries
7.10. Assumptions and Rationale
7.11. Germany
7.12. Total prevalent cases of Cancer Cachexia in Germany
7.13. Cancer Cachexia cases based on Tumor Type in Germany
7.14. Gender-Specific cases of Cancer Cachexia in Germany
7.15. France
7.16. Total prevalent cases of Cancer Cachexia in France
7.17. Cancer Cachexia cases based on Tumor Type in France
7.18. Gender-Specific cases of Cancer Cachexia in France
7.19. Italy
7.20. Total prevalent cases of Cancer Cachexia in Italy
7.21. Cancer Cachexia cases based on Tumor Type in Italy
7.22. Gender-Specific cases of Cancer Cachexia in Italy
7.23. Spain
7.24. Total prevalent cases of Cancer Cachexia in Spain
7.25. Cancer Cachexia cases based on Tumor Type in Spain
7.26. Gender-Specific cases of Cancer Cachexia in Spain
7.27. UK
7.28. Total prevalent cases of Cancer Cachexia in the United Kingdom
7.29. Cancer Cachexia cases based on tumor type in the United Kingdom
7.30. Gender-Specific cases of Cancer Cachexia in the United Kingdom
7.31. Japan
7.32. Assumptions and Rationale
7.33. Total prevalent cases of Cancer Cachexia in Japan
7.34. Cancer Cachexia cases based on tumor type in Japan
7.35. Gender-Specific cases of Cancer Cachexia in Japan

8. Current Treatment Practices
8.1. Treatment Algorithm
8.2. Treatment Guidelines- ESPEN

9. Unmet Needs

10. KOL Views

11. Bibliography

12. Appendix
12.1. Report Methodology

13. The Publisher's Capabilities

14. Disclaimer

15. About the Publisher
Note: Product cover images may vary from those shown
Adroll
adroll